Exicure is a clinical-stage biotechnology company developing therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid (SNA) technology. Co. is working to develop its SNA therapeutic candidates through multiple clinical trials, including the trial of AST-008 in cancer patients. Co. is developing XCUR-FXN, an SNA-based therapeutic candidate for the treatment of Friedreich's ataxia. XCUR17 is an SNA that targets the mRNA that encodes interleukin 17 receptor alpha, or IL-17RA, a protein that is considered essential in the initiation and maintenance of psoriasis. The XCUR stock yearly return is shown above.
The yearly return on the XCUR stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the XCUR annual return calculation with any dividends reinvested as applicable (on ex-dates).
|